Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo Company has signed a collaborative agreement with Cobrek Pharmaceuticals, a newly formed entity of Pentech Pharmaceuticals.
Subscribe to our email newsletter
Pentech will contribute its ANDA filing for a generic equivalent to Luxiq foam, a $34 million branded pharmaceutical product, to the agreement. Perrigo will contribute two of its early stage generic topical pipeline products. The parties will share the development costs and profits generated by these products, with Perrigo being the exclusive distributor.
Perrigo will also invest $12.5 million in cash in Cobrek in exchange for a minority ownership position. Pentech will contribute to Cobrek all of its interests in current and future ANDA filings including a potential first-to-file on a generic version of Hectorol (doxercalciferol).
Joe Papa, chairman and CEO of Perrigo, said: “We believe that these new and future products will expand Perrigo’s leadership position in this category and provide an opportunity for us to improve returns on one of our core businesses.”